MTD:NYE-Mettler-Toledo International Inc. (USD)

EQUITY | Diagnostics & Research | New York Stock Exchange

Last Closing

USD 1346.08

Change

0.00 (0.00)%

Market Cap

USD 10.87B

Volume

0.15M

Analyst Target

USD 865.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Mettler-Toledo International Inc is engaged in the supply of precision instruments and services. It is a provider of weighing instruments for use in laboratory, industrial and food retailing applications.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-07 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
DHR Danaher Corporation

-0.49 (-0.18%)

USD 197.82B
IQV IQVIA Holdings Inc

+2.44 (+1.07%)

USD 42.80B
A Agilent Technologies Inc

+0.42 (+0.29%)

USD 41.65B
LH Laboratory Corporation of Amer..

+0.93 (+0.43%)

USD 18.06B
DGX Quest Diagnostics Incorporated

-1.34 (-0.88%)

USD 17.19B
QGEN Qiagen NV

+0.03 (+0.07%)

USD 10.05B
CRL Charles River Laboratories

+1.15 (+0.61%)

USD 9.79B
VNRX Volitionrx Ltd

+0.12 (+16.21%)

USD 0.06B
ENZ Enzo Biochem Inc

+0.01 (+0.88%)

USD 0.06B
TMO Thermo Fisher Scientific Inc

-2.31 (-0.38%)

N/A

ETFs Containing MTD

MCSE Martin Currie Sustainable.. 5.12 % 0.00 %

-0.01 (-1.02%)

N/A
EPRE 4.58 % 0.00 %

N/A

N/A
BMED BlackRock Future Health E.. 2.86 % 0.00 %

+0.15 (+-1.02%)

USD 4.21M
ASRP:XETRA BNP Paribas Easy ECPI Glo.. 2.39 % 0.00 %

+0.01 (+-1.02%)

N/A
XMLC:F L&G Clean Water UCITS ETF 2.27 % 0.00 %

N/A

N/A
MTUSD:PA BNP Paribas Easy ECPI Glo.. 2.19 % 0.00 %

-0.11 (-1.02%)

N/A
XLVE:CA Mulvihill U.S. Health Car.. 1.82 % 0.00 %

N/A

N/A
HECO 0.00 % 0.95 %

N/A

N/A
IBB iShares Biotechnology ETF 0.00 % 0.47 %

+1.29 (+-1.02%)

USD 7.60B
QRI:CA 0.00 % 1.06 %

N/A

N/A
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.00 %

N/A

CAD 0.01B
YXM.B:CA 0.00 % 0.69 %

N/A

N/A
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.39 %

+0.31 (+-1.02%)

CAD 0.27B
MJJ 0.00 % 0.00 %

N/A

N/A
MJO 0.00 % 0.00 %

N/A

N/A
DWEQ 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.97% 100% F 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.97% 100% F 73% C
Trailing 12 Months  
Capital Gain 6.07% 85% B 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.07% 85% B 40% F
Trailing 5 Years  
Capital Gain 56.24% 75% C 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 56.24% 75% C 72% C
Average Annual (5 Year Horizon)  
Capital Gain 17.62% 92% A 82% B
Dividend Return 17.62% 92% A 80% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 31.18% 31% F 33% F
Risk Adjusted Return 56.51% 85% B 77% C+
Market Capitalization 10.87B 69% C- 92% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 30.90 42% 17%
Price/Book Ratio 3,980.99 8% 0%
Price / Cash Flow Ratio 29.94 15% 9%
Price/Free Cash Flow Ratio 24.72 23% 10%
Management Effectiveness  
Return on Equity 29.51% 92% 91%
Return on Invested Capital 48.71% 92% 97%
Return on Assets 20.32% 100% 99%
Debt to Equity Ratio -1,259.60% 100% 99%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector